As an experienced expert in psychiatric therapeutics, Creative Biolabs provides comprehensive custom services to identify potential selective norepinephrine reuptake inhibitor (SNRI) efficiently. Our specialized and dedicated team is available to support our clients with R&D, pre-clinical, and clinical development programs.
Norepinephrine (NE) has an essential modulatory role in neurotransmission and is involved in numerous physiological functions and pathological conditions. Reuptake of NE by the NE transporter (also known as uptake 1) is the primary mechanism by which NE's biological effects in the synapse are terminated. This reuptake of NE plays a vital role in the CNS, and uptake inhibition has been a valuable index identifying novel drugs for various psychiatric disorders.
SNRI with Psychiatric Disorders
Given the pharmacological profile, the potent and specific SNRI is expected to be a selective and potent tool for psychopharmacological research. These drugs bind to the NET and block the reuptake of NE. The pharmacological action of these drugs at the synapse is rapid, i.e., uptake is inhibited upon binding to the transporter. The use of SNRI in the clinic will help clarify the role NE plays in many psychiatric disorders. Moreover, the clinical significance of these drugs may contribute to the broad therapeutic efficacy in the treatment of depression, panic disorder, post-traumatic stress disorder, schizophrenia, and generalized anxiety disorder.
Reboxetine is the first potent and specific SNRI that has been developed specifically as first-line therapy for major depressive disorder. Early published data on reboxetine indicated that it has selectivity for NETs and neurochemical properties characteristic of an antidepressant. Therefore, reboxetine presents a valuable therapeutic tool to investigate the role of NE in depression and antidepressant therapy and provides a rational alternative for patients resistant to conventional antidepressant therapy (e.g., selective serotonin reuptake inhibitors). While most clinical studies with reboxetine have been conducted in patients with major depression, there is preliminary evidence for the efficacy of this drug in other psychiatric conditions such as obsessive-compulsive disorder, seasonal affective disorder, panic disorder narcolepsy, and bulimia nervosa.
SNRI Development at Creative Biolabs
The pharmacological specificity of SNRI has provided psychopharmacology with a tool to elucidate the role of NE in brain function, both under physiological and pathological conditions. Because the NE system is of fundamental importance in the pathophysiology of depression and mood disorders, Creative Biolabs brings our customers impeccable services with the testing and development of SNRI, supporting clinical and pre-clinical research in the psychiatric field. Based on leading-edge technologies and profound knowledge in NE functional mechanisms, we will help our customers accelerate the development and potential application of SNRI as a particular drug.
As a pioneer and undisputed global leader, Creative Biolabs has hugely experienced specialists who provide expert advice and an enormous breadth of advanced technologies to support our customers' SNRI development. If you are considering developing SNRI, please do not hesitate to contact us for more details.
For Research Use Only.
